TME Pharma N.V. Cash Flow-to-Debt Ratio
TME Pharma N.V. cash flow-to-debt ratio. TME Pharma N.V. (ALTME) has a Cash Flow-to-Debt Ratio of -0.15x as of December 2025, meaning its operating cash flow of €-557.00K could theoretically repay 0% of its total liabilities (€3.72 Million) in one year. Check TME Pharma N.V. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of TME Pharma N.V. (2014–2025)
Cash flow-to-debt ratio of TME Pharma N.V. from 2014 to 2025. Historical debt coverage capacity for TME Pharma N.V. across 12 annual periods. Also explore net asset growth rate of TME Pharma N.V. to track the company's year-over-year net asset growth rate.
TME Pharma N.V. Cash Flow-to-Debt Ratio by Year (2014–2025)
TME Pharma N.V. cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for TME Pharma N.V.. For the full cash flow conversion analysis, see ALTME cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.92x | €-3.42 Million | €3.72 Million | ▲ +64.5% |
| 2024 | -2.59x | €-4.63 Million | €1.79 Million | ▼ -27.8% |
| 2023 | -2.02x | €-5.63 Million | €2.79 Million | ▼ -8.5% |
| 2022 | -1.86x | €-12.14 Million | €6.51 Million | ▲ +20.7% |
| 2021 | -2.35x | €-12.38 Million | €5.27 Million | ▼ -33.0% |
| 2020 | -1.77x | €-5.22 Million | €2.96 Million | ▼ -47.9% |
| 2019 | -1.20x | €-4.29 Million | €3.59 Million | ▼ -112.9% |
| 2018 | -0.56x | €-4.00 Million | €7.12 Million | ▲ +35.8% |
| 2017 | -0.87x | €-4.24 Million | €4.85 Million | ▲ +48.0% |
| 2016 | -1.68x | €-8.99 Million | €5.35 Million | ▼ -62.9% |
| 2015 | -1.03x | €-13.48 Million | €13.07 Million | ▲ +22.7% |
| 2014 | -1.33x | €-12.46 Million | €9.33 Million | — |